|
If the control values are found to be outside acceptable limits on more than one occasion during a reading frame of twenty tests, investigation into the possible source of error is required. Possible problem areas are indicated in table 1.
Table 1: Potential sources of error in disc diffusion antimicrobial susceptibility testing.
Possible source of error
|
Detail to check
|
Test conditions
|
Excessive pre-incubation before discs applied
Excessive pre-diffusion before plates incubated
Incorrect incubation temperature
Incorrect incubation atmosphere
Incorrect incubation time
Inadequate illumination of plates when reading
Incorrect reading of zone edges
|
Medium
|
Required susceptibility testing agar not used
Not prepared as required by the manufacturer’s instructions
Batch to batch variation
Antagonists present (e.g. with sulphonamides and trimethoprim)
Incorrect pH
Incorrect divalent cation concentration
Incorrect depth of agar plates
Agar plates not level
Expiry date exceeded
|
Antimicrobial discs
|
Wrong agent or content used
Labile agent possibly deteriorated
Light sensitive agent left in light
Incorrect storage leading to deterioration
Disc containers opened before reaching room temperature
Incorrect labelling of disc dispensers
Expiry date exceeded
|
Control strains
|
Contamination
Mutation
Incorrect inoculum density
Uneven inoculation
Old culture used
|
8. Reporting susceptibility results when controls indicate problems
Microbiologists must use a pragmatic approach, as results from repeat testing are not available on the same day. If results with control strains are out of range the implications for test results need to be assessed.
Control results out of range
If control zones are below range but test results are susceptible, or control zones are above range but test results are resistant, investigate possible sources of error but report the test results. Otherwise it may be necessary to suppress reports on affected agents, investigate and retest.
Atypical results
If results are atypical with clinical isolates, the purity of the isolate and identification should be confirmed and the susceptibility repeated. Suppress the results for individual agents and retest.
Table 2: Acceptable zone diameter (mm) ranges for control strains on Iso-Sensitest agar, plates incubated at 35-37 0C in air for 18-20 h.
|
Antimicrobial agent
|
Disc content
(g unless stated)
|
Escherichia coli
|
Pseudomonas aeruginosa
|
Staphylococcus aureus
|
Enterococcus faecalis
| |
NCTC
10418
|
ATCC
25922
|
NCTC
115601
|
NCTC
10662
|
ATCC
27853
|
NCTC
6571
|
ATCC
25923
|
ATCC
29212
|
Amikacin
|
30
|
24-27
|
23-27
|
-
|
21-30
|
26-32
|
25-30
|
25-29
|
-
|
Ampicillin
|
10
|
21-26
|
16-22
|
-
|
-
|
-
|
-
|
-
|
26-35
|
Ampicillin
|
25
|
24-30
|
21-28
|
-
|
-
|
-
|
42-50
|
40-46
|
-
|
Amoxicillin
|
10
|
20-24
|
13-18
|
-
|
-
|
-
|
-
|
-
|
-
|
Aztreonam
|
30
|
39-44
|
36-40
|
-
|
27-30
|
26-30
|
-
|
-
|
-
|
Azithromycin
|
15
|
-
|
-
|
-
|
-
|
-
|
27-33
|
25-30
|
15-21
|
Carbenicillin
|
100
|
-
|
-
|
-
|
20-25
|
18-23
|
-
|
-
|
-
|
Cefamandole
|
30
|
32-36
|
35-39
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefepime
|
30
|
38-43
|
37-42
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefepime- clavulanic acid
|
30/10
|
38-43
|
37-42
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefixime
|
5
|
32-36
|
27-30
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefoxitin
|
30
|
28-33
|
26-30
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefotaxime
|
30
|
36-45
|
34-44
|
-
|
20-29
|
20-24
|
-
|
-
|
-
|
Cefotaxime-clavulanic acid
|
30/10
|
39-44
|
37-42
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefotetan
|
30
|
36-41
|
34-38
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefpodoxime
|
10
|
29-36
|
25-31
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefpodoxime- clavulanic acid
|
10/1
|
29-36
|
25-31
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefpirome
|
30
|
34-43
|
36-43
|
-
|
-
|
-
|
-
|
-
|
-
|
Ceftaroline
|
5
|
33-37
|
30-34
|
-
|
-
|
-
|
30-33
|
28-31
|
-
|
Ceftazidime
|
30
|
32-40
|
31-39
|
-
|
29-37
|
27-35
|
-
|
-
|
-
|
Ceftazidime-clavulanic acid
|
30/10
|
31-39
|
30-36
|
-
|
-
|
-
|
-
|
-
|
-
|
Ceftizoxime
|
30
|
44-49
|
40-44
|
-
|
-
|
-
|
-
|
-
|
-
|
Ceftriaxone
|
30
|
41-46
|
37-42
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefuroxime
|
30
|
25-32
|
24-29
|
-
|
-
|
-
|
-
|
-
|
-
|
Cefalexin
|
30
|
21-28
|
16-21
|
-
|
-
|
-
|
-
|
-
|
-
| Cefradine |
30
|
19-25
|
16-22
|
-
|
-
|
-
|
-
|
-
|
-
| Cephalothin |
30
|
22-26
|
17-21
|
-
|
-
|
-
|
-
|
-
|
-
|
Chloramphenicol
|
10
|
21-27
|
20-29
|
-
|
-
|
-
|
20-26
|
19-27
|
-
|
Ciprofloxacin
|
1
|
31-40
|
31-37
|
-
|
21-28
|
24-30
|
25-32
|
17-22
|
14-19
| Ciprofloxacin |
5
|
-
|
-
|
-
|
29-37
|
31-37
|
-
|
-
|
21-27
| Clarithromycin |
2
|
-
|
-
|
-
|
-
|
-
|
25-30
|
24-28
|
-
|
Clindamycin
|
2
|
-
|
-
|
-
|
-
|
-
|
30-35
|
26-33
|
No zone
|
Co-amoxiclav
|
3
|
-
|
-
|
-
|
-
|
-
|
32-38
|
27-32
|
-
|
Co-amoxiclav
|
30
|
18-31
|
20-26
|
12-18
|
-
|
-
|
42-50
|
37-44
|
-
|
Colistin
|
25
|
15-19
|
16-20
|
-
|
17-20
|
16-20
|
-
|
-
|
-
|
Cotrimoxazole
|
25
|
33-38
|
28-34
|
-
|
-
|
-
|
-
|
31-35
|
-
|
Cotrimoxazole incubation @ 300C
|
25
|
35-39
|
31-34
|
-
|
-
|
-
|
-
|
-
|
-
|
Doripenem
|
10
|
-
|
-
|
-
|
33-37
|
41-45
|
-
|
-
|
-
|
Doxycycline
|
30
|
-
|
-
|
-
|
-
|
-
|
35-40
|
33-37
|
-
|
Ertapenem
|
10
|
35-41
|
35-39
|
-
|
-
|
-
|
-
|
-
|
-
|
Erythromycin
|
5
|
-
|
-
|
-
|
-
|
-
|
22-31
|
22-29
|
-
|
Fosfomycin trometamol/G6P
|
200/50
|
29-33
|
36-41
|
-
|
-
|
-
|
25-32
|
25-30
|
27-31
|
Fusidic acid
|
10
|
-
|
-
|
-
|
-
|
-
|
32-40
|
30-37
|
-
|
Gentamicin
|
10
|
21-27
|
21-27
|
-
|
20-26
|
22-28
|
24-30
|
22-29
|
-
|
Gentamicin
|
200
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
22-27
|
Imipenem
|
10
|
32-37
|
33-37
|
-
|
20-27
|
23-28
|
-
|
-
|
28-32
|
Levofloxacin
|
1
|
30-33
|
28-34
|
-
|
-
|
-
|
-
|
-
|
-
| Levofloxacin |
5
|
-
|
-
|
-
|
22-29
|
23-29
|
-
|
-
|
-
|
Linezolid
|
10
|
-
|
-
|
-
|
-
|
-
|
26-33
|
26-30
|
24-29
|
Mecillinam
|
10
|
34-39
|
30-35
|
-
|
-
|
-
|
-
|
-
|
-
|
Meropenem
|
10
|
38-42
|
27-39
|
-
|
26-33
|
32-39
|
-
|
-
|
22-28
|
Mezlocillin
|
75
|
31-36
|
27-32
|
-
|
-
|
-
|
-
|
-
|
-
|
Minocycline
|
30
|
-
|
-
|
-
|
-
|
-
|
34-39
|
33-36
|
-
|
Moxifloxacin
|
1
|
31-35
|
29-33
|
-
|
-
|
-
|
33-40
|
33-38
|
-
|
Moxifloxacin
|
5
|
-
|
-
|
-
|
19-24
|
23-27
|
-
|
-
|
-
|
Mupirocin
|
5
|
-
|
-
|
-
|
-
|
-
|
26-35
|
24-34
|
-
|
Mupirocin
|
20
|
-
|
-
|
-
|
-
|
-
|
30-38
|
27-35
|
-
|
Nalidixic acid
|
30
|
28-36
|
26-32
|
-
|
-
|
-
|
-
|
-
|
-
|
Neomycin
|
10
|
-
|
-
|
-
|
-
|
-
|
18-22
|
21-27
|
-
|
Netilmicin
|
10
|
22-27
|
22-26
|
-
|
17-20
|
20-24
|
-
|
22-28
|
-
|
Nitrofurantoin
|
200
|
25-30
|
23-27
|
-
|
-
|
-
|
21-25
|
20-26
|
-
|
Norfloxacin
|
2
|
34-37
|
32-36
|
-
|
-
|
-
|
-
|
-
|
-
|
Ofloxacin
|
5
|
31-37
|
31-38
|
-
|
18-26
|
18-25
|
-
|
-
|
|
Penicillin
|
1 unit
|
-
|
-
|
-
|
-
|
-
|
32-40
|
28-36
|
-
|
Piperacillin
|
75
|
30-35
|
27-32
|
-
|
27-35
|
27-34
|
-
|
-
|
-
|
Pip/tazobactam
|
85
|
30-35
|
26-31
|
-
|
28-35
|
28-35
|
-
|
-
|
26-32
|
Quinupristin-
Dalfopristin
|
15
|
-
|
-
|
-
|
-
|
-
|
27-31
|
-
|
12-19
|
Rifampicin
|
2
|
-
|
-
|
-
|
-
|
-
|
27-39
|
29-36
|
-
| | |
10
|
18-24
|
17-22
|
-
|
-
|
-
|
-
|
-
|
-
| Streptomycin |
300
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
20-24
|
Teicoplanin
|
30
|
-
|
-
|
-
|
-
|
-
|
17-23
|
16-20
|
19-25
|
Tetracycline
|
10
|
23-29
|
22-28
|
-
|
-
|
-
|
31-40
|
26-35
|
9-13
|
Ticarcillin
|
75
|
32-35
|
27-30
|
-
|
24-28
|
23-27
|
-
|
-
|
-
|
Ticarcillin-
clavulanic acid
|
85
|
33-37
|
27-31
|
-
|
25-29
|
24-27
|
-
|
-
|
-
|
Tigecycline
|
15
|
29-32
|
28-32
|
-
|
-
|
-
|
29-34
|
27-30
|
26-31
|
Tobramycin
|
10
|
24-27
|
23-27
|
-
|
23-30
|
26-32
|
26-31
|
29-35
|
-
|
Trimethoprim
|
2.5
|
30-37
|
25-31
|
-
|
-
|
-
|
25-30
|
20-28
|
28-35
|
Trimethoprim
|
5
|
-
|
-
|
-
|
-
|
-
|
24-34
|
-
|
-
|
Vancomycin
|
5
|
-
|
-
|
-
|
-
|
-
|
14-20
|
13-17
|
13-19
|
= -Lactamase producing strain
Table 3: Acceptable zone diameter (mm) ranges for control strains on Iso-Sensitest agar supplemented with 5% defibrinated horse blood, with or without the addition of NAD, plates incubated at 35-370C in air for 18-20 h.
-
Antimicrobial agent
|
Disc content
(g unless stated)
|
Staphylococcus aureus
|
Group A streptococci
|
NCTC 6571
|
ATCC 25923
|
NCTC 8198
|
ATCC 19615
|
Amoxicillin
|
2
|
25-29
|
-
|
-
|
-
|
Cefuroxime
|
5
|
20-27
|
-
|
-
|
-
|
Chloramphenicol
|
10
|
17-23
|
-
|
-
|
-
|
Clindamycin
|
2
|
-
|
-
|
25-28
|
29-35
|
Co-amoxiclav
|
2/1
|
29-36
|
-
|
-
|
-
|
Erythromycin
|
5
|
26-33
|
23-29
|
-
|
-
|
Nalidixic acid
|
30
|
6-9
|
-
|
-
|
-
|
Penicillin
|
1 unit
|
30-41
|
27-35
|
-
|
-
|
Tetracycline
|
10
|
30-38
|
28-36
|
-
|
-
|
Table 4: Acceptable zone diameter ranges for control strains for detection of methicillin/oxacillin/cefoxitin resistance in staphylococci (methicillin/oxacillin incubated at 300C; cefoxitin incubated at 350C).
-
|
|
|
Staphylococcus aureus
|
Antimicrobial agent
|
Medium
|
Disc content (g)
|
NCTC 6571
|
ATCC
25923
|
NCTC
12493a
|
Methicillin
|
Columbia/Mueller Hinton agar + 2% NaCl
|
5
|
18-30
|
18-28
|
No zone
|
Oxacillin
|
Columbia/Mueller Hinton agar + 2% NaCl
|
1
|
19-30
|
19-29
|
No zone
|
Cefoxitin
|
ISA
|
10
|
26-31
|
24-29
|
10-20
|
a Methicillin/oxacillin/cefoxitin- resistant strain.
Table 5: Acceptable zone diameter (mm) ranges for control strains on Iso-Sensitest agar supplemented with 5% defibrinated horse blood and NAD, plates incubated at 35-370C in 10% CO2 /10% H2/80% N2 for 18-20 h.
-
Antimicrobial agent
|
Disc content
(g unless stated)
|
Bacteroides fragilis
NCTC 9343
|
Bacteroides thetaiotaomicron
ATCC 29741
|
Clostridium perfringens
NCTC 8359
|
Clindamycin
|
2
|
13-27
|
11-25
|
23-28
|
Co-amoxiclav
|
30
|
43-49
|
-
|
40-45
|
Meropenem
|
10
|
42-50
|
36-43
|
39-45
|
Metronidazole
|
5
|
34-43
|
26-40
|
11-23
|
Penicillin
|
1 unit
|
6
|
6
|
26-30
|
Piperacillin/tazobactam
|
75/10
|
41-48
|
-
|
37-43
|
Table 6: Acceptable zone diameter (mm) ranges for control strains on Iso-Sensitest agar supplemented with 5% defibrinated horse blood with or without the addition of NAD, plates incubated at 35-370C in 4-6% CO2 for 18-20 h.
|
Antimicrobial agent
|
Disc content
( g unless stated)
|
Pasteurella
multocida
|
Neisseria
gonorrhoeae
(with NAD)
|
Staphylococcus aureus
|
Haemophilus influenzae
(with NAD)
|
Streptococcus pneumoniae
|
NCTC 8489
|
NCTC 12700
|
NCTC 6571
|
ATCC 25923
|
NCTC 11931
|
ATCC 49247a
|
ATCC
49619
| Amoxicillin |
2
|
-
|
-
|
29-34
|
-
|
20-26
|
No zone
|
-
|
Ampicillin
|
2
|
-
|
-
|
-
|
-
|
22-30
|
6-13
|
-
| Ampicillin |
10
|
32-37
|
-
|
-
|
-
|
-
|
-
|
-
|
Azithromycin
|
15
|
-
|
30-40
|
-
|
-
|
28-32
|
23-27
|
25-30
|
Cefaclor
|
30
|
-
|
-
|
-
|
-
|
29-38
|
No zone
|
26-33
|
Cefixime
|
5
|
-
|
33-44
|
-
|
-
|
-
|
-
|
-
|
Cefotaxime
|
5
|
35-41
|
32-44
|
-
|
-
|
33-45
|
27-38
|
27-35
|
Ceftazidime
|
30
|
-
|
-
|
-
|
-
|
39-46
|
36-41
|
-
|
Ceftizoxime
|
30
|
-
|
-
|
-
|
-
|
-
|
-
|
36-44
|
Ceftriaxone
|
5
|
-
|
33-47
|
-
|
-
|
47-54
|
38-44
|
-
|
Ceftriaxone
|
30
|
-
|
-
|
-
|
-
|
-
|
-
|
38-47
|
Cefuroxime
|
5
|
-
|
23-32
|
22-29
|
24-29
|
22-28
|
6-16
|
-
|
Chloramphenicol
|
10
|
-
|
-
|
21-26
|
-
|
30-40
|
30-38
|
21-29
|
Ciprofloxacin
|
1
|
31-37
|
40-50
|
22-29
|
18-23
|
32-40
|
33-44
|
14-21
|
Clarithromycin
|
2
|
-
|
-
|
-
|
-
|
6-10
|
No zone
|
26-31
| Clindamycin |
2
|
-
|
-
|
21-25
|
-
|
-
|
-
|
-
|
Co-amoxiclav
|
3
|
-
|
-
|
29-36
|
-
|
20-27
|
10-20
|
-
|
Co-trimoxazole
|
25
|
-
|
-
|
-
|
-
|
40-47
|
38-42
|
21-25
|
Ertapenem
|
10
|
-
|
-
|
-
|
-
|
30-38
|
25-34
|
35-40
|
Erythromycin
|
5
|
-
|
20-29
|
25-29
|
-
|
12-23
|
9-16
|
23-36
|
Imipenem
|
10
|
-
|
-
|
-
|
-
|
32-39
|
31-36
|
-
|
Levofloxacin
|
1
|
-
|
-
|
-
|
-
|
38-43
|
35-41
|
17-21
| Linezolid |
10
|
-
|
-
|
22-26
|
-
|
-
|
-
|
-
| Meropenem |
10
|
-
|
-
|
-
|
-
|
38-45
|
33-39
|
-
| Moxifloxacin |
1
|
-
|
-
|
-
|
-
|
36-42
|
33-39
|
24-30
|
Nalidixic acid
|
30
|
-
|
32-40
|
9-17
|
9-17
|
33-38
|
33-39
|
-
|
Ofloxacin
|
5
|
-
|
-
|
-
|
-
|
39-49
|
38-44
|
21-26
|
Oxacillin
|
1
|
-
|
-
|
-
|
-
|
-
|
-
|
8-16
|
Penicillin
|
1 unit
|
24-28
|
12-20
|
37-44
|
29-36
|
-
|
-
|
-
|
Quinupristin-
Dalfopristin
|
15
|
-
|
-
|
-
|
-
|
-
|
-
|
21-29
|
Rifampicin
|
2
|
-
|
26-34
|
32-37
|
-
|
-
|
-
|
-
|
Rifampicin
|
5
|
-
|
-
|
-
|
-
|
-
|
-
|
28-35
|
Spectinomycin
|
25
|
-
|
17-23
|
-
|
-
|
-
|
-
|
-
| Teicoplanin |
30
|
-
|
-
|
14-19
|
-
|
-
|
-
|
-
| Telithromycin |
15
|
-
|
-
|
-
|
-
|
26-31
|
22-26
|
33-40
|
Tetracycline
|
10
|
29-34
|
27-35
|
33-40
|
27-34
|
27-35
|
9-14
|
26-36
|
Tigecycline
|
15
|
-
|
-
|
27-30
|
24-28
|
-
|
-
|
26-30
|
Trimethoprim
|
2.5
|
-
|
-
|
-
|
-
|
30-40
|
28-36
|
-
| Vancomycin |
5
|
-
|
-
|
12-16
|
-
|
-
|
-
|
-
|
a -Lactamase-negative, ampicillin-resistant strain
Table 7: Acceptable zone diameter (mm) ranges for control strains on Iso-Sensitest agar supplemented with 5% defibrinated horse blood with or without the addition of NAD, plates incubated at 420C in microaerophilic conditions for 24h.
|
Antimicrobial agent
|
Disc content
( g unless stated)
|
Staphylococcus aureus
|
NCTC 6571
|
ATCC 25923
|
Nalidixic acid
|
30
|
12-17
|
14-17
|
Erythromycin
|
5
|
22-27
|
20-25
|
Ciprofloxacin
|
1
|
22-26
|
22-26
|
Share with your friends: | 
